InVirtuoLabs is a biotech startup founded in Lugano, Switzerland, in 2024. Its legal name is In Virtuo Laboratories SA. It combines machine learning, including generative chemistry, with physics-based molecular simulations to find and optimize drug candidates. The company runs its own drug discovery projects, offers its virtual laboratory platform, and co-develops drugs with pharmaceutical companies. It is supported by the USI Startup Centre incubation program.
Products & services2 products · 1 service
productLive since July 2025
InVirtuo Platform
End-to-end AI drug discovery platform that combines machine learning with physics-based molecular simulations.
+ What's included
For: Pharmaceutical and biotech companies
InVirtuoMOL: molecular machine learning engine that assesses the properties of drug candidates
InVirtuoGEN: multimodal generative AI for designing new molecules
InVirtuoSIM: physics-based simulations
service
Co-development with pharma
Joint R&D projects in which the platform is used to design and optimize drug candidates for a partner.
+ What's included
For: Pharmaceutical and biotech companies
Covers hit identification, lead optimization and ADMET prediction
productIn development
Proprietary drug discovery pipeline
In-house drug candidates for metabolic and neurological disorders.
+ What's included
Four internal candidates, IVL-001 to IVL-004
Stages listed range from hit discovery to preclinical validation
Customers
Pharmaceutical and biotech companies that work with InVirtuoLabs on co-development projects.
Traction
Updated Oct 2026
€2.3MEurostars grant for the NEUROSPARK project it leads
4in-house drug candidates in the pipeline
Billionsmolecules generated and evaluated daily by its chemical language model
Co-development with pharmaceutical companies is one of the three pillars of its business model, and it already works with several pharmaceutical and biotech firms on co-development projects.In the company's own words
Openfor.co network
Put your company on Openfor. Get found.
Show your products, customers and traction to founders, investors and partners across 30+ countries.